21-DEC-2024 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 Y 1 OBI-3424 8mg 64 5 0 0 0 0 0 02/08/2021 59 23
        2 OBI-3424 10mg   5 0 0 0 0 0      
        3 OBI-3424 12mg   8 4 3 1 0 0      
            18 4 3 1 0 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 42 11 6 2 1 0 03/02/2021 253 98
        2 Early V-O   81 27 13 7 2 0      
            123 38 19 9 3 0      
 
  MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental 1 Y 2 Venetoclax + Daunorubicin + Cytarabine 335 1 1 1 1 0 0 09/25/2024 158 63
        3 Venetoclax + Azacitidine   1 1 1 1 0 0      
        4 (Daunorubicin + Cytarabine) Liposome   2 2 2 2 1 0      
        5 (Daunorubicin + Cytarabine) Liposome + Venetoclax   1 1 1 1 0 0      
            5 5 5 5 1 0      
 
  MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials 1 Y 1 Screening   189 189 186 157 65 15 06/18/2024 232 95
            189 189 186 157 65 15      
 
    2 Y 2 Re-screening   10 10 10 10 6 2 06/18/2024    
            10 10 10 10 6 2      
 
Yes A042001-B-Cell ALL, Inotuzunab+chemo v Standard chemo 0 E Total Registrations   9 7 7 4 2 1 10/12/2023 137 47
            9 7 7 4 2 1      
 
    1 E Total Registrations   7 5 5 3 1 0 10/12/2023    
            7 5 5 3 1 0      
 
  EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   5 0 0 0 0 0 02/24/2023 76 16
            5 0 0 0 0 0      
 
    1 E Total Registrations   3 0 0 0 0 0 02/24/2023    
            3 0 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   71 0 0 0 0 0 11/09/2018 242 85
            71 0 0 0 0 0      
 
    1 E Total Registrations   57 0 0 0 0 0 11/09/2018    
            57 0 0 0 0 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 1 0 0 0 0 08/13/2020 136 56
            11 1 0 0 0 0      
 
    1 E Total Registrations   5 1 0 0 0 0 08/13/2020    
            5 1 0 0 0 0      
 
  EA9171-CML, Anti-PD-1 Pembrolizumab + TKIs 0 E Total Registrations   4 1 0 0 0 0 02/18/2020 64 35
            4 1 0 0 0 0      
 
    1 E Total Registrations   4 1 0 0 0 0 02/18/2020    
            4 1 0 0 0 0      
 
    2 E Total Registrations   1 0 0 0 0 0 02/18/2020    
            1 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   49 14 9 4 3 2 02/19/2021 179 60
            49 14 9 4 3 2      
 
    1 E Total Registrations   39 9 5 2 2 1 02/19/2021    
            39 9 5 2 2 1      
 
    2 E Total Registrations   34 7 5 1 1 1 02/19/2021    
            34 7 5 1 1 1      
 
  MM1OAEA02-MyeloMATCH: AML, New Dx, Ven+HMA 1 E Total Registrations   2 2 2 2 2 1 12/02/2024 44 10
            2 2 2 2 2 1      
 
  MM1YACTG01-AML, New/Young/Intermediate, Ven+Chemo 1 E Total Registrations   2 2 2 2 0 0 10/14/2024 152 52
            2 2 2 2 0 0      
 

21-DEC-2024 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 3 Randomization 14-Oct-20 179 60
MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials 3 Re-screening 16-May-24 232 95
  4 Re-screening 16-May-24 232 95

21-DEC-2024 6:10

LEUK Recently Closed Studies Accrual Report

OPEN Study Date
Closed		 Reg. Arm Total
Regs		 Regs
Last
30 Days		 Regs
Last
7 Days
E EA9171-CML, Anti-PD-1 Pembrolizumab + TKIs 17-Dec-24 0 Total Registrations 4 0 0
      1 Total Registrations 4 0 0
      2 Total Registrations 1 0 0